Suppr超能文献

朊病毒在变异型克雅氏病前驱期和症状期患者血浆中的检测。

Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease.

机构信息

Etablissement Français du Sang, INSERM, Université de Montpellier, UMR 1058, TransDiag, F-34184 Montpellier, France.

Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Institut du Cerveau et de la Moelle épinière (ICM)-Hôpital Pitié-Salpêtrière, F-75013 Paris, France.

出版信息

Sci Transl Med. 2016 Dec 21;8(370):370ra182. doi: 10.1126/scitranslmed.aag1257.

Abstract

Variant Creutzfeldt-Jakob disease (vCJD) is a human prion disease resulting from the consumption of meat products contaminated by the agent causing bovine spongiform encephalopathy. Evidence supporting the presence of a population of silent carriers that can potentially transmit the disease through blood transfusion is increasing. The development of a blood-screening assay for both symptomatic vCJD patients and asymptomatic carriers is urgently required. We show that a diagnostic assay combining plasminogen-bead capture and protein misfolding cyclic amplification (PMCA) technologies consistently detected minute amounts of abnormal prion protein from French and British vCJD cases in the required femtomolar range. This assay allowed the blinded identification of 18 patients with clinical vCJD among 256 plasma samples from the two most affected countries, with 100% sensitivity [95% confidence interval (CI), 81.5 to 100%], 99.2% analytical specificity (95% CI, 95.9 to 100%), and 100% diagnostic specificity (95% CI, 96.5 to 100%). This assay also allowed the detection of silent carriage of prions 1.3 and 2.6 years before the clinical onset in two blood donors who later developed vCJD. These data provide a key step toward the validation of this PMCA technology as a blood-based diagnostic test for vCJD and support its potential for detecting presymptomatic patients, a prerequisite for limiting the risk of vCJD transmission through blood transfusion.

摘要

变异型克雅氏病(vCJD)是一种人类朊病毒病,由摄入受牛海绵状脑病病原体污染的肉类产品引起。越来越多的证据支持存在一群无症状的隐性携带者,他们可能通过输血传播这种疾病。迫切需要开发一种用于检测有症状的 vCJD 患者和无症状携带者的血液筛查检测方法。我们展示了一种结合纤维蛋白原珠捕获和蛋白错误折叠环扩增(PMCA)技术的诊断检测方法,能够在所需的飞摩尔范围内从法国和英国的 vCJD 病例中持续检测到微量异常朊病毒蛋白。该检测方法可在 256 份来自两个受影响最严重国家的血浆样本中,盲法识别 18 名具有临床 vCJD 的患者,其敏感性为 100%[95%置信区间(CI),81.5%至 100%],分析特异性为 99.2%(95%CI,95.9%至 100%),诊断特异性为 100%(95%CI,96.5%至 100%)。该检测方法还可以在两名后来发展为 vCJD 的献血者的血液中检测到潜伏期为 1.3 年和 2.6 年前的 prion 隐性携带。这些数据为验证该 PMCA 技术作为 vCJD 的血液诊断检测方法提供了关键步骤,并支持其检测亚临床患者的潜力,这是通过输血限制 vCJD 传播风险的前提。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验